New indication for mometasone breathlessly awaited

The use of Schering-Plough's corticosteroid mometasone in the treatment of asthma was the focus of several studies presented at the 56th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) [San Diego, US; March 2000]. Three studies presented at the AAAAI meeting, all supported by Schering-Plough Research Institute, examined the use of mometasone, administered via a dry powder inhaler ['Asmanex'], in various groups of patients aged ≥ 12 years who had asthma.